Hospital admissions caused by adverse drug events: an Australian prospective study

Australian Health Review : a Publication of the Australian Hospital Association
Alexandra L PhillipsSepehr Shakib

Abstract

To assess the frequency of adverse drug event (ADE)-related admissions (ADE-RAs) during a prospective medical record review of patients admitted to a metropolitan tertiary referral hospital. Potential ADE-RA cases were identified by examination of case records of randomly selected patients. Cases were assessed by an expert panel to measure study outcomes, which were the frequency (ADEs and ADE-RAs) as well as type, likelihood of causality, severity, avoidability and detection of ADEs. Of the 370 subjects, 59 (16.0%) had a confirmed ADE-RA, with 15 (4.1%) of these serious and preventable. The 59 ADE-RAs were a result of 72 discreet ADEs. Adverse drug reactions were the most common type of ADE, followed by non-compliance. Of the 72 discreet ADEs, 31.9% were classified as 'probable' or 'highly probable'. Most ADEs (54.2%) were classified as 'definitely avoidable', 34.7% were classified as 'severe' and 21.8% were classified as both 'definitely avoidable' and 'severe'. Half the ADEs were detected after the patient had been admitted and most were detected by medical practitioners. Antineoplastics followed by antidiabetic agents were most frequently implicated. Implementing a systems approach that involves multiple strategies, such as...Continue Reading

References

Aug 1, 1981·Clinical Pharmacology and Therapeutics·C A NaranjoD J Greenblatt
Feb 1, 1993·The Annals of Pharmacotherapy·S R GuharoyJ McGalliard
Jun 3, 1996·The Medical Journal of Australia·J G DartnellR F Moulds
Feb 18, 1998·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Mar 30, 1999·Journal of Quality in Clinical Practice·A MalpassW B Runciman
Apr 7, 1999·European Journal of Clinical Pharmacology·R RaschettiC La Guidara
Jul 18, 2001·Internal Medicine Journal·M ChanJ H Vial
Aug 14, 2001·Pharmacoepidemiology and Drug Safety·A K JhaD W Bates
Dec 9, 2003·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·William B RuncimanRobert J Adams
Oct 27, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Annalisa CapuanoFilomena Mazzeo
Feb 1, 2005·Pharmacoepidemiology and Drug Safety·Gianluca TrifiròAchille P Caputi
Apr 6, 2006·The Medical Journal of Australia·Elizabeth E Roughead, Joel Lexchin
Apr 6, 2006·The Medical Journal of Australia·Graeme C MillerLisa Valenti

❮ Previous
Next ❯

Citations

Mar 6, 2015·Expert Opinion on Drug Metabolism & Toxicology·April K MarroneIgor P Pogribny
Jun 27, 2015·Basic & Clinical Pharmacology & Toxicology·Outi Lapatto-ReiniluotoPertti J Neuvonen
Apr 19, 2015·BMJ Supportive & Palliative Care·N A MorganD C Currow
Oct 4, 2018·Internal Medicine Journal·Hanwen ZhangNicholas Glasgow
Mar 7, 2019·Pharmacoepidemiology and Drug Safety·Marc TorkaJoel Lexchin
Jul 20, 2018·Internal Medicine Journal·Richard McNeillMatthew Doogue
Aug 7, 2017·International Psychogeriatrics·D WuchererW Hoffmann
Jul 2, 2019·Therapeutic Advances in Drug Safety·Abubakar Ibrahim JatauAhmed Awaisu
Nov 18, 2020·Australian Health Review : a Publication of the Australian Hospital Association·Martin CanningErin Dunn
Nov 15, 2020·European Journal of Clinical Pharmacology·Mirjam KauppilaOuti Lapatto-Reiniluoto
Aug 10, 2021·Therapeutic Advances in Drug Safety·Chariclia ParadissisMichael Barras
Sep 1, 2021·The International Journal of Pharmacy Practice·Kaeshaelya ThiruchelvamTherese Kairuz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the American Medical Informatics Association : JAMIA
Peter M KilbridgeThomas C Bailey
The Annals of Pharmacotherapy
Hélène PeyriereSylvie Hansel
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
B L SenstD W Bates
Pharmacoepidemiology and Drug Safety
Gianluca TrifiròAchille P Caputi
© 2021 Meta ULC. All rights reserved